China biotech unicorn Innovent in talks on $200M IPO and new funding — report
A little more than a year ago, Shanghai-based Innovent Biologics raised a record $260 million D round for its efforts to lead the first biosimilar …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
